Key Drivers
- Strong Cash Flow
- Margin Compression
- High Intangibles
AIAI Summary
JNJ is now a premium-valued pipeline-execution investment rather than a defensive dividend play, so investors should require clear evidence that new launches can offset STELARA-era erosion while preserving margins before adding exposure.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Margin Compression
- •High Intangibles
JNJ's strong profitability and cash generation support its quality, but elevated valuation, softer quarterly margins, and high intangibles warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Support Holding
- •Resistance Capping
- •Range Consolidation
JNJ is stabilizing above $265–$267 support but remains range-bound unless it breaks $275–$278 resistance.
Pullback from $278.43 to $265.58 indicates short-term selling pressure
Sentiment & News
Key News Insights:
- •Pipeline Momentum
- •Stelara Pressure
- •Valuation Concerns
J&J's strong pipeline and launches support growth, but Stelara erosion, MedTech weakness, litigation, and valuation concerns warrant a cautious HOLD stance.
Near-term earnings volatility may persist despite improving long-term growth prospects
Similar Companies in Healthcare
Other companies in the same sector with AI ratings